Current Opinion in Gastroenterology was launched in 1985. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of gastroenterology is divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editors for this issue.
Ciarán P. Kelly
Ciarán P. Kelly, MD, is Professor of Medicine at Harvard Medical School, Director of Gastroenterology Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center, Boston, Massachussets, USA. Dr Kelly earned his medical degree from Trinity College in Dublin, Ireland where he was a Foundation Scholar and recipient of numerous academic awards. Dr Kelly has also received postgraduate clinical and research awards from the Crohn's and Colitis Foundation of America, the American Gastroenterological Association and the National Institutes of Health. He is an American Gastroenterology Association Fellow and a Fellow of the American College of Gastroenterology.
Dr Kelly has longstanding clinical and research interests in intestinal infection and inflammation. He has been involved in patient care and research in Clostridium difficile infection for more than 25 years and leads NIH-funded research programs that evaluate potential C. difficile vaccines and other immune-based treatments. His interest in the pathophysiology, diagnosis and management of celiac disease is also longstanding and, as Medical Director of the Celiac Center at BIDMC which he founded in 2004, he heads clinical, research and educational programs in celiac disease.
Dr Kelly has served as a committee member of the NIH, Center for Scientific Review as well as FDA, CDC and NIH committees on celiac disease and C. difficile infection. Dr Kelly is the author of more than 250 clinical and basic research book chapters, invited reviews, and peer-reviewed, original articles appearing in such journals as Infection & Immunity, American Journal of Physiology, Gastroenterology, Journal of Biological Chemistry, Journal of Clinical Investigation, New England Journal of Medicine and Lancet.
Mark H. Wilcox
Prof. Wilcox is Chair of PHE's Rapid Review Panel (reviews the utility of infection prevention & control products for the NHS), Deputy Chair of the UK Department of Health's Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and is a member of the PHE's Programme Board on Healthcare Associated Infection & Antimicrobial Resistance. He is a member of the Medical Research Council's Infections and Immunity Board, and the Scientific Advisory Board for the EU Innovative Medicines Initiative's COMBACTE-NET consortium. From 2017, he was seconded one day per week to NHS Improvement to support the delivery of the new national target to reduce healthcare associated Gram-negative blood stream infections in England.
He has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years), Clinical Director of Pathology (6 years) at LTHT and Head of Microbiology (15 years).
He is an advisor to the Department of Health in England on healthcare associated infections (HCAIs), the UK EPIC/NICE projects, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection, the Wellcome Trust and CARB-X panel on novel antimicrobials, and the European Centre for Disease Control. He is a member of UK, European and US working groups on C. difficile infection, and is on the Editorial Boards of Lancet Gastroenterology & Hepatology, Journal of Hospital Infection and Infectious Diseases in Clinical Practice. He has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents, 1998–2016.
Professor Wilcox heads a Healthcare Associated Infection research team at the University of Leeds (http://medhealth.leeds.ac.uk/hcai), comprising around 30 doctors, scientists and nurses; projects include multiple aspects of Clostridium difficile infection, diagnostics, antibiotic resistance and the gut microbiome, staphylococcal infection, and the clinical development of new antimicrobial agents. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for 15 clinical trials of new anti-infective drugs, 1999–2018, has carried out multiple NIHR portfolio studies on healthcare associated infection topics, and is currently supplying central laboratory services for several clinical trials of antimicrobial agents. He has authored >470 papers and published a number of books and chapters. He is co-editor of Antimicrobial Chemotherapy (5th/6th/7th Eds, 2007/12/15).
Eamonn M.M. Quigley
Eamonn M.M. Quigley is Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Houston, Texas, USA, Professor of Medicine at Weill Cornell Medical College and David M Underwood Chair of Medicine in Digestive Disorders. A graduate of University College Cork, Ireland, Dr Quigley trained in internal medicine in Glasgow and Manchester, and in gastroenterology in Glasgow, the Mayo Clinic, USA, Rochester, Minnesota and Manchester. In 1986, he joined the faculty at the University of Nebraska Medical Center in Omaha, Nebraska, USA, where he ultimately served as Chief of Gastroenterology and Hepatology. Returning to Cork in 1998, he served as Dean of the Medical School at UCC for 7 years and was a principal investigator at its Alimentary Pharmabiotic Center from its inception. He served as president of both the American College of Gastroenterology and the World Gastroenterology Organization and is a past editor-in-chief of the American Journal of Gastroenterology. Clinical and research interests include irritable bowel syndrome, gastrointestinal motility and the role of the gut microbiota in health and in gastrointestinal and metabolic disorders.